

Mark Nelson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5240966/publications.pdf>

Version: 2024-02-01

63
papers

2,193
citations

331670

21
h-index

223800

46
g-index

63
all docs

63
docs citations

63
times ranked

3208
citing authors

#	ARTICLE	IF	CITATIONS
1	Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV. <i>HIV Medicine</i> , 2022, 23, 936-946.	2.2	12
2	Indirect Human Immunodeficiency Virus Morbidity and Mortality Due to Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, 1947-1949.	5.8	2
3	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. <i>Journal of Hepatology</i> , 2021, 75, 829-839.	3.7	27
4	Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-90.	0.7	0
5	Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. <i>Hepatology</i> , 2020, 72, 7-18.	7.3	24
6	Use of Coronary Artery Calcium Scoring to Improve Cardiovascular Risk Stratification and Guide Decisions to Start Statin Therapy in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 98-105.	2.1	12
7	COVID-19 in patients with HIV. <i>Lancet HIV</i> , 2020, 7, e383.	4.7	19
8	Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. <i>Lancet</i> , 2020, 395, 888-898.	13.7	98
9	High rates of unprotected anal sex and use of generic direct-acting antivirals in a cohort of MSM with acute HCV infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 627-634.	2.0	6
10	Bariatric surgery in individuals with human immunodeficiency virus and type 2 diabetes: a case series. <i>Journal of Medical Case Reports</i> , 2019, 13, 146.	0.8	1
11	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 296-304.	1.6	36
12	Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV mono-infection independently of the gut microbiome and bacterial translocation. <i>Aids</i> , 2019, 33, 805-814.	2.2	20
13	Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 207-215.	2.1	1
14	Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir. <i>Journal of NeuroVirology</i> , 2019, 25, 85-90.	2.1	11
15	The Association between Detected drug Resistance Mutations and CD4 ⁺ T-Cell Decline in HIV-Positive Individuals Maintained on a Failing Treatment Regimen. <i>Antiviral Therapy</i> , 2018, 23, 105-116.	1.0	3
16	Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study. <i>Journal of Infection</i> , 2017, 74, 401-407.	3.3	15
17	Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. <i>Blood</i> , 2017, 129, 2143-2147.	1.4	52
18	An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2075-2082.	3.0	10

#	ARTICLE	IF	CITATIONS
19	Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. <i>Lancet HIV</i> , 2017, 4, e295-e302.	4.7	47
20	Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 103-111.	1.2	16
21	Telaprevir-Containing Triple Therapy in Acute HCV Coinfection: The CHAT Study. <i>Antiviral Therapy</i> , 2017, 22, 619-623.	1.0	10
22	HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. <i>Journal of Hepatology</i> , 2017, 66, 282-287.	3.7	154
23	Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. <i>HIV Clinical Trials</i> , 2017, 18, 118-125.	2.0	16
24	Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials. <i>Infection and Chemotherapy</i> , 2016, 48, 219.	2.3	2
25	Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with <i>CYP2B6</i> c.516G>T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4511-4518.	3.2	18
26	Does the presence of a mutation at position V179 impact on virological outcome in patients receiving antiretroviral medication?. <i>Journal of Infection</i> , 2016, 72, 632-633.	3.3	1
27	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? <i>Epidemiological and Modeling Insights. Clinical Infectious Diseases</i> , 2016, 62, 1072-1080.	5.8	122
28	Hepatitis C and sex. <i>Clinical Medicine</i> , 2016, 16, 189-192.	1.9	20
29	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2928-2937.	3.0	7
30	Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. <i>Journal of NeuroVirology</i> , 2016, 22, 852-860.	2.1	48
31	CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. <i>Cytokine</i> , 2016, 83, 139-146.	3.2	22
32	Telaprevir-based therapy in patients coinfecting with chronic hepatitis C virus infection and HIV: INSIGHT study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 244-250.	3.0	2
33	Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. <i>Lancet</i> , 2015, 385, 1098-1106.	13.7	170
34	Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. <i>Lancet HIV</i> , 2015, 2, e319-e327.	4.7	285
35	Factors influencing combination antiretroviral therapy choice: Do doctors really know best?. <i>Journal of Infection</i> , 2015, 71, 269-271.	3.3	2
36	Inpatient admissions of patients living with HIV in two European centres (UK and Italy); comparisons and contrasts. <i>Journal of Infection</i> , 2015, 70, 690-694.	3.3	5

#	ARTICLE	IF	CITATIONS
37	Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme. <i>Journal of Infection</i> , 2015, 71, 675-682.	3.3	1
38	A comparison of inpatient admissions in 2012 from two European countries. <i>Journal of the International AIDS Society</i> , 2014, 17, 19712.	3.0	4
39	Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19626.	3.0	7
40	Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors. <i>Journal of the International AIDS Society</i> , 2014, 17, 19827.	3.0	1
41	Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure. <i>Journal of the International AIDS Society</i> , 2014, 17, 19737.	3.0	0
42	Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials. <i>AIDS Research and Treatment</i> , 2014, 2014, 1-7.	0.7	7
43	Do resistance patterns vary between different FTC containing drug regimens?. <i>Journal of Infection</i> , 2014, 68, 503-505.	3.3	1
44	Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection. <i>Vaccine</i> , 2014, 32, 7005-7013.	3.8	14
45	Cerebral vasculitis and encephalitis due to Epstein-Barr virus in a patient with newly diagnosed HIV infection. <i>Journal of Clinical Virology</i> , 2014, 59, 264-267.	3.1	18
46	The utility of cerebrospinal fluid analysis in the investigation and treatment of neurosyphilis. <i>Sexually Transmitted Infections</i> , 2014, 90, 451-451.	1.9	3
47	THE BURDEN OF NEUROLOGICAL DISEASE IN THE ACUTE INPATIENT HIV POPULATION; AN AUDIT OF 73 CONSECUTIVE ADMISSIONS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.165-e2.	1.9	0
48	Targeted treatment of HHV-8-associated multicentric Castleman's disease. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 189-198.	0.8	1
49	Efficacy and safety of rilpivirine in treatment-naïve, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2020-2028.	3.0	35
50	The features and outcome of HIV-associated anal cancer in screened and unscreened populations. <i>Journal of Clinical Oncology</i> , 2012, 30, e14574-e14574.	1.6	2
51	A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naïve, HIV-1-infected population. <i>Aids</i> , 2011, 25, 335-340.	2.2	36
52	HIV-related lymphoma. <i>HIV Therapy</i> , 2010, 4, 649-659.	0.6	7
53	Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus Optimized Background Therapy in the MOTIVATE 1 and 2 Trials. <i>HIV Clinical Trials</i> , 2010, 11, 145-155.	2.0	2
54	Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naïve, HIV-infected patients: 96 week ARTEMIS data. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1505-1509.	3.0	49

#	ARTICLE	IF	CITATIONS
55	Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. <i>Aids</i> , 2008, 22, 1374-1376.	2.2	40
56	8th International Congress on Drug Therapy in HIV Infection. <i>Future Virology</i> , 2007, 2, 153-156.	1.8	15
57	Maraviroc. <i>Drugs</i> , 2007, 67, 2289-2290.	10.9	0
58	Abacavir Plasma Pharmacokinetics in the Absence and Presence of Atazanavir/Ritonavir or Lopinavir/Ritonavir and Vice Versa in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2007, 12, 825-830.	1.0	28
59	An Open-Label, Randomized Comparative Pilot Study of a Single-Class Quadruple Therapy Regimen versus a 2-â€“Class Triple Therapy Regimen for Individuals Initiating Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2006, 11, 73-78.	1.0	33
60	Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 404-412.	2.1	151
61	Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen. <i>Antiviral Therapy</i> , 2004, 9, 423-429.	1.0	26
62	Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. <i>Nature Medicine</i> , 2000, 6, 76-81.	30.7	401
63	Pneumococcal vaccination and HIV infection. <i>International Journal of STD and AIDS</i> , 1998, 9, 1-7.	1.1	15